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Abstract
Introduction. Chronic venous insufficiency is one of the most common medical conditions among highly 
developed societies. The majority of patients (70%) suffer from saphenous veins incompetency. The study 
presents results of a 3-month follow-up of application of venous mechanochemical ablation system with the 
FlebogrifTM catheter.
Material and methods. The study was conducted on 200 patients, including 170 women and 30 men 
treated with ablation with FlebogrifTM to treat varicose veins. All patients were qualified based on the ultrasound 
in a standing position confirming incompetence of the great saphenous vein or small saphenous vein. The vein 
was punctured under ultrasound guidance in the distal part of the incompetent segment. The area of vascular 
access was anesthetized with 0.5 mL of 1% lignocaine. The compression therapy in the form of the first grade 
medical elastic stocking was used after the surgery.
Results. The initial technical success of the surgery was achieved in all the patients. During the 3-month 
follow-up, recanalization occurred in 8 cases, in 5 patients great saphenous vein and in 3 small saphenous 
vein recanalised. Based on the recommendations of the European Consensus Meeting on Foam Sclerotherapy, 
7 cases were defined as complete recanalization and 1 as partial. The analysis of numerical data obtained with 
Venous Clinical Severity Score and Clinics Ethiology Anatomy Pathophysiology Classification showed a statistically 
significant decrease in the severity of clinical symptoms compared to ones before the surgery and between 
particular days of the observation during the 3-month follow-up.
Conclusions. The procedure is highly effective reaching 96% at 3 months of follow-up, provides good cosmetic 
effect and the low rate of complications. Minimal invasiveness of mechanochemical ablation with Flebogrif™ 
may improve the quality of life during the postoperative period. A long-term observation is recommended to 
achieve a full-value assessment of this novel method. 
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Introduction
Chronic venous insufficiency is one of the most 
common medical conditions in the world. The World 
Health Organization defines varicose veins of the lower 
limbs as dilated superficial veins presenting as baggy or 
cylindrical in shape and possessing damaged valves [1]. 
In 70% of cases saphenous veins are affected [2]. It is 
reported that 40–60% of women and 25–30% of men 
will present symptoms of venous insufficiency during 
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life time [3]. The disease can initially be asymptomatic. 
After this asymptomatic period, varicose veins may 
result in thrombotic complications and venous ulcers. 
Traditional methods of surgical treatment of varicose 
veins are being increasingly replaced by less invasive 
thermal ablation. The effectiveness of this approach 
has been confirmed in numerous clinical studies. Re-
cent years have brought new, promising non-thermal 
ablation techniques to the forefront, including mech-
anochemical ablation (MOCA). Two-years follow-up 
of the ClariVein system application proved, that the 
method was significantly less traumatic compared to 
thermal methods with its efficacy reaching 96% [3]. 
This study presents the results of a 3-month fol-
low-up of application of venous mechanochemical 
ablation system with the FlebogrifTM catheter. 
Material and methods
The study was conducted on 200 patients, includ-
ing 170 women and 30 men diagnosed by means of 
Doppler ultrasound with great saphenous vein/small 
saphenous vein insufficiency. All patients qualified for 
mechanochemical ablation of the saphenous vein using 
the FlebogrifTM system. The study has been approved 
by Bioethics Committee of the Medical University of 
Lublin (0254/226/2015). Patient demographics are 
presented in Table 1. 
Measurement of saphenous vein diameter was per-
formed in a standing position on three levels: 1–2 cm 
from the saphenofemoral junction, in the mid-thigh, and 
at the height of the knee fissure. The diameter of the sa-
phenous vein in women in the region of the saphenofem-
oral junction averaged 8.89 mm (range 4.1–20.4 mm), 
in the mid-thigh 6.96 mm (3.5–17.1 mm), and at the 
level of knee fissure 5.88 mm (9.3–11.9 mm). In men, 
the diameter below saphenofemoral junction averaged 
8.82 mm (5–22 mm), in the mid-thigh 7.45 mm (3.8– 
–11.2 mm), and at the level of the knee fissure 6.8 mm 
(3.2–10.4 mm). The results of measurements of GSV 
(great saphenous vein) diameter are presented in 
Table 2.
All procedures were performed in the operating 
room. Under ultrasound guidance, the site of GSV 
puncture was evaluated and then chosen, usually below 
the knee joint and at the site of the lowest reflux level to 
provide maximum technical success. The puncture was 
performed using the Seldinger needle provided with 
the kit, through which the guiding wire was inserted so 
that its end was located in the region of saphenofemoral 
junction. Before insertion of the 6F introducer sheath, 
the skin was locally anesthetized with 1% lignocaine at 
the puncture site. Table 3 presents the region where 
the FlebogrifTM catheter was inserted. 
Using the guiding wire, the FlebogrifTM system 
was inserted placing its working part 2 cm below the 
saphenofemoral junction. The system was freed by 
sliding the external sheath in relation to the internal 
mandrile. The five arms of the working part with sharp 
hooks on the ends were released and directed toward 
the wall of the vessel and scarification of the vein was 
performed from the positioning site to the puncture site 
by withdrawing the system with continuous movement. 
The speed at which the system was slid amounted to 
Table 1. Patients demographics
Sex Number  
of patients
Age Total
Females 170 87 56 18
200
Males 30 75 46 23
Table 2. The diameter of the punctured vein, numerical distribution depending on the side (right, left), sex, and the rate of punc-
tured GSV/SSV
Diameter of the vein (from-to/average) Operated limb Proportion
Below SFJ Mid-thigh Knee level Females Males GSV SSV
Right Left Right Left
4.2–22.1/8.1 3.8–17.1/6.2 3.8–11.9/6.6 68 102 13 17 172 (86%) 28 (14%)
Table 3. The region where FlebogrifTM catheter was inserted
Sex Puncture site
Above the knee Knee level Below the knee
Females 37 36 97
Males 7 6 18
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5 cm/s and the volume of the injected foam amounted to 
1 mL/5 cm of vein. For veins with a diameter of 15 mm 
2% polidocanol was used, and for veins of larger dia-
meter 3% polidocanol.
The volume of the sclerosant used for saphenous 
vein ablation ranged from 3 to 10 mL with an average 
of 6.5 mL.
After the operation, compression therapy was used 
with second grade compression stockings (Sigvaris®) 
for a minimum of 10 days. Enoxaparin was chosen for 
patients with increased risk of thromboembolism at 
a dose of 1 × 40 mg s.c. for 10 days. Follow-up visits 
were scheduled at one, three, six, and 12 months after 
procedure. 
The patients qualified for treatment with MOCA 
were evaluated using CEAP, VCSS (Clinics Etiology, 
Anatomy, Pathophysiology Classification and Venous 
Clinical Severity Score), and the Analog Pain Scale.
Results
Figure 1 presents numerical distribution of patients 
participating in a follow-up, during which the effective-
ness of ablation was evaluated in the form of an index 
of treated vein occlusion, pain severity estimated with 
ten-point visual analog scale (VAS), VCSS, and CEAP. 
Table 4 presents staging of clinical symptoms in evaluated 
patients at baseline. Analysis of VAS data demonstrated 
a significant decrease in pain severity at each follow-up 
time point compared to the initial pain level (Fig. 2).
Analysis of numerical data obtained via VCSS and 
CEAP showed a statistically significant decrease in the 
severity of clinical symptoms compared to baseline lev-
els and at each day of observation during the 3-month 
follow-up. Due to the non-parametric data distribution, 
analyses were performed using the Friedman ANOVA 
and Wilcoxon test. The level of significance was set at 
p < 0.05. Figures 3, 4, and 5 present statistical analysis 
of the results obtained during the 3-month follow-up 
period. The effectiveness of MOCA with the Flebog-
rifTM catheter was estimated based on the ratio of the 
number of closed veins to the number of recanalization.
During the 3-month follow-up, eight cases of reca-
nalization occurred, 5 concerning the great saphenous 
vein and 3 concerning the small saphenous vein. Based 
on the recommendations of the European Consensus 
Meeting on Foam Sclerotherapy, 7 cases were defined 
Table 4. Staging of clinical symptoms in evaluated patients at 
baseline
Scale Min. Average Max.
VCSS 7 14 21
CEAP 2 4 6
Figure 1. Numerical distribution of the patients participating in subsequent follow-up visits
Figure 2. Graphical analysis of pain severity estimated with VAS throughout the study
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as complete recanalization and 1 as partial. All cases 
where ablation with FlebogrifTM was not successful 
concerned women.
Complementary obliteration was performed in 92 pa- 
tients (76 women, 16 men) during the follow-up visit 
4 weeks after treatment. The volume of sclerosant foam 
ranged from 3 to 7 mL and the polidocanol concen-
ration from 1–2%. 
During follow-up, a young man who before the 
treatment presented with a low risk of thromboembo-
lism was diagnosed with deep vein thrombosis in the 
operated limb. Further tests after thrombosis onset 
revealed thrombophilia due to mutation of Factor V 
Leiden. Superficial vein thrombosis of the lower limb 
was diagnosed in 29 cases, and 20 patients presented 
hyperpigmentation after ablation. There were no 
complications related to the obliterating agent applied. 
Discussion
Percutaneous intravascular ablation methods for 
insufficient superficial veins were introduced in the late 
1990s and became a good, minimally invasive alternative 
to surgical intervention. Radiofrequency ablation (RF) 
presented in 1998 was the first of the aforementioned 
techniques to be introduced [3]. A year later, a new 
method based on Endovenous Laser Treatment (EVLT) 
was announced. At present, this method is the most 
commonly used in the treatment of varicose veins of 
the lower extremities [4]. Open versus endovascular 
treatment options tend to divide phlebologists into 
enthusiasts and skeptics, who believe that minimally 
invasive procedures have low effectiveness due to 
lack of crossectomy or ligation of the saphenofemoral 
junction [5]. However, this was not confirmed in long- 
-term studies and the relapse risk in new methods was 
estimated to be comparable to stripping [1]. In 2008, 
a new method of thermal venous ablation using steam, 
steam vein sclerosis (SVS), was proposed. This method 
allows for removal of any kind of varicose veins, includ-
ing their tributaries and recurrent varicose veins [6].
The most commonly observed side effects associ-
ated with thermal ablation, including pain, paresthesia, 
hematoma, and transient skin discoloration, occur in 
a relatively small percentage of patients. Other serious 
complications, such as injury of the deep veins, iatro-
genic arteriovenous fistula, or pulmonary embolism 
caused by fragment of a broken laser fiber, are uncom-
mon [7–11]. 
Other promising treatment options include 
non-thermal methods based on mechanical-chemical 
venous ablation (MOCA), cyanoacrylate adhesives, or 
microfoam obliteration. All these methods, which are 
free of thermal effects, cause less trauma and fewer 
local complications and provide a valid alternative to 
thermal methods. Mechanochemical ablation with the 
ClariVein system is the best known method, which is 
characterized by high effectiveness, reaching 96% in 
a 2-year follow-up. This is the first hybrid technique 
that works by mechanical irritation of the vessels with 
simultaneous sclerotherapy. The patient is mobilized 
directly after surgery and may return to normal activity 
the very next day. The advantage of this method is that 
it does not exert a thermal effect, and therefore does 
not require tumescent anesthesia. There is also no risk 
of skin burns, nerve or muscle damage, and postopera-
Figure 5. Estimation of pain severity with the VAS
Figure 3. Evaluation of the clinical symptom severity  
estimated with the VCSS
Figure 4. Evaluation of the clinical symptom severity  
estimated with CEAP classification
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tive pain and the risk of thrombotic complications are 
significantly lower [12]. 
Bishawi et al. indicate that this procedure has a very 
high effectiveness, reaching 97% in the first 6 weeks 
after the procedure. Effectiveness is maintained at 
the level of 96% over 2 years of follow-up [13]. Elias 
estimated the effectiveness at 96.7% in a follow-up 
lasting 260 days [14]. He also did not report compli-
cations, such as skin or nerve damage. A total of 28% 
of patients presented with small hematomas, 17% had 
local skin hardening, and 18% felt discomfort for more 
than a week after the procedure. High effectiveness 
of this method over follow-up periods ranging from 
6 to 24 months has been confirmed in several other 
studies [15–20].
Due to the relatively low number of procedures 
performed and a short follow-up period, this technique 
requires further trials. It is expected that currently on-
going comparative studies of mechanochemical ablation 
and thermal techniques, such as EVLT and RF will allow 
establishment of MOCA as a strong alternative to the 
current dominant intravenous methods of varicose vein 
treatment [21–23].
The new, alternative system of mechanochemical 
ablation presented in this study, FlebogrifTM, is signif-
icantly simpler than ClariVein. Unlike the ClariVein 
system, FlebogrifTM does not require an expensive 
starting system; furthermore, it eliminates the risk of 
wedging on the venous valves at lower rotation rpm. 
When performing operations on a small diameter vein 
(< 4 mm) the risk of vessel perforation in the Flebog-
rifTM system appears to be minimal. The system also 
allows effective operation in veins with a diameter 
exceeding 20 mm, which is not recommended for the 
ClariVein system. The results of 3 months of follow-up 
are comparable with the results of ClariVein system 
application. Moreover, our results are consistent with 
the preliminary results of other authors using this spe-
cific technique, however based on the smaller group 
of patients. Ciostek et al. in their preliminary study, 
reported efficacy of the system reaching 94.9% after 
3 months of follow-up [24].
Conclusions
The FlebogrifTM system provides high efficiency, 
high occlusion rate and technical success after three 
months of follow-up reaching 96%. The system is 
also characterized by good cosmetic effect and low 
complication rate. The procedure performed with the 
FlebogrifTM catheter seems to improve patient quality 
of life in postoperative period. A long-term follow-up is 
indicated for complete evaluation of the quality of the 
MOCA method with the FlebogrifTM catheter. 
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